Revenues expected to be ahead of consensus by approximately 7% driven by an increased global demand for expanded product, service and IP offering
Cambridge, UK – 19th January 2014: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the “Group”), the international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, today announces a trading update ahead of its full year results for the twelve months ended 31 December 2014. The Group intends to announce its preliminary full year 2014 results on 14 April 2015.
The Group reports a successful year and expects full year 2014 revenues to be ahead of consensus expectations of £11.0 million by approximately 7%, representing growth in excess of 77% over prior year (year ended 31 December 2013: £6.7 million). In addition, the Group is eligible to receive future R&D milestones of up to £158 million plus future product royalties (year ended 31 December 2013: £120m).
This strong performance has been driven by an increased global demand for Horizon’s fully integrated commercial offering comprising research tools, services and intellectual property including drug targets, drug biomarkers and drug candidates. Horizon worked with 30 of the world’s top 50 Pharmaceutical and Biopharmaceutical companies during the year (year ended 31 December 2013: 21) and 961 organisations in total (year ended 31 December 2013: 353). The Horizon offering enables its customers to translate human genome sequencing data into innovative medicines and companion diagnostic tests that improve clinical outcomes for patients and economic outcomes for drug developers and healthcare payers alike.
Molecular diagnostic reagent products, genome-editing services and combination drug screening services have contributed significantly to the growth in revenue and in customer breadth and depth. Revenue includes consolidated contributions following the successful integration of two strategic acquisitions completed in 2014 that have broadened the Group’s capabilities and established Horizon as the world’s leading translational genomics company. Horizon Discovery Incorporated, was formed following the acquisition of the combination high-throughput screening business and assets (“CombinatoRx”) from Zalicus Incorporated (NASDAQ: ZLCS), completed on 2 June 2014, and Sage Labs, Incorporated an in vivo model development company completed on 29 September, 2014.
Financial reporting will include non-recurring exceptional items relating to the IPO and the acquisitions during the year and losses for the Group are expected to be in line with market expectations as investment continues in the long term growth of the business consistent with our previously reported strategy.
Year-end cash is expected to be reported at approximately £17m (year ended 31 December 2013: £4.2m).
Post-period end, on 8 January 2015, the Company announced the acquisition of Haplogen Genomics GmbH, a biotechnology company based in Vienna, Austria. Now renamed Horizon Genomics GmbH, the acquired company’s core haploid technology platform adds a new dimension to the Group’s commercial offering by adding a 10-fold increase in both its cell line product inventory (10,000 vs 1,000 previously) and production capacity (100s per month vs 10s per month previously) as well as a 10-fold reduction in production cost. These products have application in basic genomics research enabling access to the fast-growing academic research market not previously penetrated by the Group as well as broadening its commercial offering to those companies engaged in drug discovery and development. This also builds Horizon’s capability in generating genetic sequence, antibody, aptamer and protein validation reagents for research, process optimisation and diagnostic uses.
Dr. Darrin M. Disley, Chief Executive Officer of Horizon Discovery Group, commented:
“Last year was transformational for Horizon as we expanded from a fast-growing private company with approximately 80 employees located in Cambridge, UK, to a fully integrated global public company with over 200 employees in the UK, United States and now in Vienna, Austria.
“We have enjoyed strong revenue growth in 2014, driven both organically and through the successful acquisitions of CombinatoRx and Sage Labs. Horizon has remained focused on becoming a fully-integrated life science company and, with the integration of recent acquisitions, is now able to provide service, product and R&D solutions to customers engaged in all stages of the personalized medicine paradigm from ‘sequence to treatment’.
“This has also been a year in which Horizon cemented its leadership in the fields of genome editing and personalized medicine through the acquisition of key IP, operational capability and know-how. To support this growth, management has further developed Horizon’s talent pool, and, to this effect, we have augmented our Executive, Scientific Advisory Board as well as added high calibre business leaders to our Board to guide the Company.
“Horizon has successfully delivered on all of its 2014 goals as set out at the time of the IPO, and we are confident and very excited by the prospects for the year ahead.”
ENDS
For further information from Horizon Discovery Group plc, please contact:
Consilium Strategic Communications (Financial Media and Investor Relations)
Amber Bielecka / Mary-Jane Elliott / Jessica Hodgson / Matthew Neal
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com
Panmure Gordon & Co. (NOMAD)
Corporate Finance: Freddy Crossley / Duncan Monteith / Fred Walsh
Broking: Tom Salvesen
Tel: +44 20 7886 2500
Notes for Editors
About Horizon Discovery Group plc www.horizondiscovery.com/
Horizon is a revenue-generating life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines. Horizon has a diverse and international customer base well in excess of 1,000 organizations across nearly 50 countries, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Company supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.
Horizon’s core capabilities are built around its proprietary translational genomics platform, GENESIS™, a high-precision and flexible suite of gene editing tools able to alter almost any endogenous gene sequence of human or mammalian cell-lines. Horizon offers almost 14,000 products, almost all of which are based on the application of GENESIS™ to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These ‘patients-in-a-test-tube’ are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.
In addition, Horizon provides GENASSIST™ CRISPR and rAAV gene editing tools, custom cell line generation services for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, contract research and custom screening services and custom shRNA development services and off-the-shelf validated shRNA (through Horizon’s partner Sirion).
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”, for further information please visit: www.horizondiscovery.com.
Parkwalk University of Oxford Isis Fund II Closes Oversubscribed
University of Oxford Isis Fund II reaches funding target of £2m, closes
24 February 2015
Isis Innovation and Parkwalk announced today that the University of Oxford Isis Fund II has raised over £2 million, exceeding its funding target, and will close to new investors. The fund achieved its initial target in less than four weeks and will close at almost twice that level.
Isis Innovation executive director Linda Naylor said: “In 2014, Isis Innovation oversaw a record £2.6m in proof-of-concept funding flow into over twenty new Oxford technologies and ventures. The first University of Oxford Isis Fund was a cornerstone of this achievement, and we already have a pipeline of promising technologies which will apply to this second Fund over the coming year.
“These Funds will again play a critical role in providing finance so new companies are properly resourced for the initial stages of commercial product development.”
The University of Oxford Isis Fund I invested in stroke-diagnostics specialist Brainomix which went on to raise £1.2m and won numerous awards and grants, Oxtex, the developer of a novel intelligent tissue expander, Salunda, the manufacturer of a contactless sensor for condition monitoring and automated sentiment analysis company TheySay.
Parkwalk Advisors’ Moray Wright said: “These Funds provide private investors, particularly University of Oxford alumni and friends, with quite a unique chance to invest in early stage technology companies as they spin-out of the University.
“And as these companies become successful, investors in the funds also stand to gain from the tax reliefs offered under the Enterprise Investment Scheme and Seed Enterprise Investment Scheme.”
Since 1987, Isis Innovation has been responsible for creating spin-out companies based on academic research from the University of Oxford. It has spun-out a new company every two months on average. Over £266 million in external investment has been raised by Isis spin-out companies since 2000, and five are currently listed on London’s AIM market.
Parkwalk is a UK technology-specialist EIS fund management firm. Parkwalk aims to launch the University of Oxford Isis Fund III in Q4 2015 or Q1 2016. For further details please contact the Parkwalk funds team on 020 7759 2285.
About Isis Innovation
Isis Innovation is the research and technology commercialisation company of the University of Oxford. We provide access to technology from Oxford researchers through intellectual property licensing, spin-out company formation and material sales, and to academic expertise through Oxford University Consulting.
Isis is the highest university patent filer in the UK and is ranked 1st in the UK for university spin-outs, having created more than 100 new companies in 25 years. In the last financial year we completed 503 licenses and consulting agreements. Isis Enterprise, our innovation management consultancy, signed 85 deals with university, government and industrial clients from offices around the world.
Isis was named ‘Technology Transfer Unit of the Year 2014’ by Global University Venturing.
For updates on innovations from Oxford, follow Isis on LinkedIn and Twitter or subscribe at www.isis-innovation.com
About Parkwalk
Specialising in University spin-out companies, Parkwalk invests in innovative UK high-growth companies across various stages of their development: from growth, development and commercial capital through to acquisition finance. Investments range from early stage to AIM-listed. Parkwalk’s EIS Funds seek significant capital gains with the substantial benefits offered under the Enterprise Investment Scheme.
For updates from Parkwalk, please follow us on Twitter
Media enquiries to:
Renate Krelle
Media & Business Communications Manager, Isis Innovation Ltd
renate.krelle@isis.ox.ac.uk
T: 01865 280867
Posted on February 24, 2015
Fund Managers Comments
Oxford, UoOIF II